CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy.
about
Modulation of TCR-induced transcriptional profiles by ligation of CD28, ICOS, and CTLA-4 receptorsInvolvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade.BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccinationProgrammed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancerA Perspective of Immunotherapy for Prostate CancerTremelimumab: research and clinical developmentThe wonderous chaperones: A highlight on therapeutics of cancer and potentially malignant disordersOverview of current immunotherapeutic strategies for gliomaCTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their InhibitionFueling the engine and releasing the break: combinational therapy of cancer vaccines and immune checkpoint inhibitorsAdaptive Immune Resistance: How Cancer Protects from Immune AttackAllogeneic tumor cell vaccines: the promise and limitations in clinical trialsDuality of the immune response in cancer: lessons learned from skinImmunotherapy in the treatment of non-small cell lung cancerPrimer on tumor immunology and cancer immunotherapyNovel immunotherapies for hematologic malignanciesThe role of the immune system in non-small cell lung carcinoma and potential for therapeutic interventionCrystal structure of the receptor-binding domain of human B7-2: Insights into organization and signalingMolecular Insights into γδ T Cell Costimulation by an Anti-JAML AntibodyThe PD1:PD-L1/2 Pathway from Discovery to Clinical ImplementationIs There Still Room for Cancer Vaccines at the Era of Checkpoint InhibitorsHarnessing the Power of Onco-Immunotherapy with Checkpoint InhibitorsCD28 and CTLA-4 coreceptor expression and signal transductionCo-stimulatory pathways in lymphocyte regulation: the immunoglobulin superfamilyImmunotherapeutic strategies for the treatment of renal cell carcinoma: where are we now?Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanomaModulation of cell signaling networks after CTLA4 blockade in patients with metastatic melanomaCancer immunotherapy comes of ageHumanized Immunoglobulin Mice: Models for HIV Vaccine Testing and Studying the Broadly Neutralizing Antibody Problem.A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells.Spatiotemporal regulation of T cell costimulation by TCR-CD28 microclusters and protein kinase C theta translocation.Suppressing T cell motility induced by anti-CTLA-4 monotherapy improves antitumor effects.Murine regulatory T cells differ from conventional T cells in resisting the CTLA-4 reversal of TCR stop-signal.CD28 and ITK signals regulate autoreactive T cell trafficking.A systematic assessment of MHC class II peptide binding predictions and evaluation of a consensus approachPhase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma.CD8+ T cells are predominantly protective and required for effective steroid therapy in murine models of immune thrombocytopenia.Novel targeted therapeutics for metastatic castration-resistant prostate cancer.Redox remodeling as an immunoregulatory strategy.Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer.
P2860
Q24535662-2508436E-1902-4DEF-9A93-CF634DB19CCBQ24535835-D1A56C60-2080-4652-B8FA-DF6D20A152D6Q24652965-E86FBCC0-6B15-4588-9C99-2A798CD9FE15Q24685406-FCF13EC8-A213-4043-A889-2111E0CD445EQ26741277-98674BF6-CFF7-4ABE-A659-F788BD8BFFD2Q26752822-6FA6BD5C-A1D3-4F05-AE21-A5578CF5B292Q26775973-390F014B-C673-416F-8F57-6C0538AD8AEFQ26776345-BE7A20BD-6FF3-4146-89A9-E8B1FE684F5DQ26777563-8EE65CB1-3B83-4DCF-96B6-80EC97F54C3FQ26778793-39A5964B-0541-42BD-B134-728B525B96FDQ26798448-B30BDD1F-2BB4-4B40-864B-2FA7F7D1F560Q26852333-5A7E712F-2C2B-4CAD-A92B-3F21CDBCF118Q26999379-57414DA9-F01A-4309-B604-E6745FB3D149Q27000382-56865FA6-2688-4F81-AF1B-5AE7BDDF1C3CQ27001126-CB2EDB75-0A93-4F76-855B-DF949FBD680AQ27004436-13AA5743-4E68-48B2-B8B2-931E31656E0EQ27024781-F7A1FB82-60FB-4CD8-BFD8-B8D22A6EFEC5Q27640589-01A93BC3-B846-442A-A755-2F96E53DD533Q27666534-E2AB6FAA-2D02-4C9E-9008-6B99191775F8Q28066941-0D1CE2A5-2D43-42EA-B655-7E654E3743D7Q28072532-20949750-41B2-4090-88FF-5DC5C2377279Q28086999-707ABF1A-42BC-436D-9126-5A47FE5D1271Q28244243-9E9E3D9C-751B-4B4D-89E9-9CE878E5111BQ28271806-C59B9419-30F9-4F8A-986D-A64A17D6E80DQ28301672-54978725-B049-4199-9910-FCE223B841D2Q28307216-9AC255A3-EBE4-46EB-946B-A97CC91544FCQ28749278-BB95B7EE-6B6B-43DE-8ECA-9E34519D6A4DQ29619918-AFEF9776-79D1-4433-9890-94DF06A3A0BFQ30234773-79AB207F-1DF5-41EB-B846-7A4C95EDF3ACQ30440525-CED10ABB-0FB7-4834-B96C-0D56B7B7A20BQ30496881-EE2D65CE-9AF6-4DBA-A0D7-89CECFF444A7Q30525394-249EE125-C43A-4B6C-96ED-2A096AB82792Q30533331-D8014BBE-2F6A-45AF-A349-4BDA02DC0C66Q30577349-1BB28C4E-AE7A-4214-BF15-FEC7C36A1900Q33326976-BC2278AC-ACD2-4069-A55C-6F88746B719FQ33386521-3A6FF1C3-7392-4AD4-A5ED-1FBC841C88E1Q33423336-DAB91D27-6441-4950-B9EB-6EC449DEC52EQ33642278-0843694B-6711-4F8A-ADCB-A15E95FE5A0CQ33648194-A7C97DF2-0BA3-4229-8C9C-95D82920F631Q33689478-2E54455B-744A-40D4-B837-58A6685FB36B
P2860
CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
CTLA-4-mediated inhibition in ...... lation in tumor immunotherapy.
@ast
CTLA-4-mediated inhibition in ...... lation in tumor immunotherapy.
@en
type
label
CTLA-4-mediated inhibition in ...... lation in tumor immunotherapy.
@ast
CTLA-4-mediated inhibition in ...... lation in tumor immunotherapy.
@en
prefLabel
CTLA-4-mediated inhibition in ...... lation in tumor immunotherapy.
@ast
CTLA-4-mediated inhibition in ...... lation in tumor immunotherapy.
@en
P2093
P1476
CTLA-4-mediated inhibition in ...... lation in tumor immunotherapy.
@en
P2093
C A Chambers
J P Allison
P304
P356
10.1146/ANNUREV.IMMUNOL.19.1.565
P577
2001-01-01T00:00:00Z